جمعه 21 شهریور 1404
[Archive]
دوره 23، شماره 5 - ( 2-1404 )
جلد 23 شماره 5 صفحات 382-377 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khalili A. The role of tacrolimus in women with unexplained infertility: A narrative review. IJRM 2025; 23 (5) :377-382
URL: http://ijrm.ir/article-1-3472-fa.html
URL: http://ijrm.ir/article-1-3472-fa.html
نقش تاکرولیموس در زنان مبتلا به نازایی با علت ناشناخته: یک بررسی مروری. International Journal of Reproductive BioMedicine. 1404; 23 (5) :377-382
چکیده: (330 مشاهده)
اختلالات ایمونولوژیک و اتوایمیون متعددی میتوانند باعث نازایی شوند. حدود 20-10% نازاییها مربوط به فاکتورهای ایمنی مادر و جنین میباشد. استفاده از درمانهای ایمونولوژیک در زنان مبتلا به نازایی یک رویکرد درمانی جدیدی است. تاکرولیموس یک مهارکننده کلسینورین است که در برخی مطالعات مشخص شده میتواند با ایجاد تولرانس و مهار سلولهای Natural killer cell و Natural killer T cell و ماکروفاژها از سقط جنین جلوگیری کند. ما در این مطالعه اثرات تاکرولیموس در سقط جنین و شکست متدهای کمکباروری را مورد ارزیابی قرار میدهیم. جستجوی مقالات در پایگاههای PubMed، Scopus، Google Scholar و Web of Science با استفاده از کلمات کلیدی و Mesh Term هایTacrolimus [mh], FK506, infertility [mh], abortion, spontaneous [mh], recurrent miscarriage, recurrent pregnancy loss, and recurrent implantation failure صورت گرفت. ما معتبرترین و جدیدترین تحقیقات در زمینه نازایی را مورد ارزیابی قرار دادیم. تاکرولیموس نسبتا در طی حاملگی بدون عارضه بود و هیچگونه عوارض عمدهای در جنین و مادر نداشت. تاکرولیموس در زنانی که نسبت T helper-1/T helper-2 افزایش یافته داشتند مفید بود. در آینده مطالعاتی باید طراحی شود که دوز مؤثر، دوره درمان، زمان شروع تاکرولیموس، و زمان قطع درمان را مشخص کند.
نوع مطالعه: Review article |
فهرست منابع
1. Khalili A, Sadeghi B. Chronic urticaria in pregnancy: Physiologic and hormonal background for an immune skin disease. J South Asian Feder Obst Gynae 2024; 16: 145-149. [DOI:10.5005/jp-journals-10006-2381]
2. Andreescu M. The impact of the use of immunosuppressive treatment after an embryo transfer in increasing the rate of live birth. Front Med 2023; 10: 1167876. [DOI:10.3389/fmed.2023.1167876] [PMID] [PMCID]
3. Abolhassani H, Tavakol M, Chavoshzadeh Z, Mahdaviani SA, Momen T, Yazdani R, et al. National consensus on diagnosis and management guidelines for primary immunodeficiency. Immunol Genet J 2019; 2: 8-20.
4. Lorzadeh N, Kazemirad N. The role of natural killer cells and mast cells in female infertility and associated treatment outcomes. Curr Womens Health Rev 2020; 16: 102-106. [DOI:10.2174/1573404816666200206111550]
5. Zare Moghaddam M, Zare F, Sandoghsaz R, Khalili A, Shams A. Human V α 7.2-J α 33 mucosal-associated invariant T cells in endometrial ectopic tissues tend to produce interferon-gamma: A new player in endometriosis etiology: A case-control study. Int J Reprod BioMed 2023; 22: 235-244. [DOI:10.18502/ijrm.v22i3.16168] [PMID] [PMCID]
6. Koninckx PR, Ussia A, Adamyan L, Wattiez A, Gomel V, Martin DC. Pathogenesis of endometriosis: The genetic/epigenetic theory. Fertil Steril 2019; 111: 327-340. [DOI:10.1016/j.fertnstert.2018.10.013] [PMID]
7. Cavalcante MB, Tavares ACM, Rocha CA, de Souza GF, Lima EM, Simões JML, et al. Calcineurin inhibitors in the management of recurrent miscarriage and recurrent implantation failure: Systematic review and meta-analysis. J Reprod Immunol 2023; 160: 104157. [DOI:10.1016/j.jri.2023.104157] [PMID]
8. Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. Nat Rev Dis Primers 2020; 6: 98. [DOI:10.1038/s41572-020-00228-z] [PMID]
9. RPL EGGo, Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: Recurrent pregnancy loss. Hum Reprod Open 2018; 2018: hoy004. [DOI:10.1093/hropen/hoy004] [PMID] [PMCID]
10. Wang Q, Sun Y, Fan R, Wang M, Ren C, Jiang A, et al. Role of inflammatory factors in the etiology and treatment of recurrent implantation failure. Reprod Biol 2022; 22: 100698. [DOI:10.1016/j.repbio.2022.100698] [PMID]
11. Mukherjee N, Sharma R, Modi D. Immune alterations in recurrent implantation failure. Am J Reprod Immunol 2023; 89: e13563. [DOI:10.1111/aji.13563] [PMID]
12. Ebrahimi F, Omidvar-Mehrabadi A, Shahbazi M, Mohammadnia-Afrouzi M. Innate and adaptive immune dysregulation in women with recurrent implantation failure. J Reprod Immunol 2024; 164: 104262. [DOI:10.1016/j.jri.2024.104262] [PMID]
13. Yamaguchi K. Tacrolimus treatment for infertility related to maternal-fetal immune interactions. Am J Reprod Immunol 2019; 81: e13097. [DOI:10.1111/aji.13097] [PMID]
14. Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus-pharmacokinetic considerations for clinicians. Curr Drug Metab 2018; 19: 342-350. [DOI:10.2174/1389200219666180101104159] [PMID]
15. Ong SC, Gaston RS. Thirty years of tacrolimus in clinical practice. Transplantation 2021; 105: 484-495. [DOI:10.1097/TP.0000000000003350] [PMID]
16. Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab 2018; 19: 513-522. [DOI:10.2174/1389200219666180129151948] [PMID] [PMCID]
17. Kitada A, Nakai T, Fukui S, Rokutanda R, Okada M, Kusaoi M, et al. Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus: A retrospective single-center analysis in Japan. Lupus 2023; 32: 352-362. [DOI:10.1177/09612033221148334] [PMID]
18. Lee H, Myoung H. Review of two immunosuppressants: Tacrolimus and cyclosporine. J Korean Assoc Oral Maxillofac Surg 2023; 49: 311-323. [DOI:10.5125/jkaoms.2023.49.6.311] [PMID] [PMCID]
19. Hisano M, Nakagawa K, Kwak-Kim J, Sugiyama R, Sago H, Yamaguchi K. Changes in the T-helper 1 and 2 cell populations during pregnancy in tacrolimus-treated women with repeated implantation failure and recurrent pregnancy loss. Hum Fertil 2022; 25: 975-982. [DOI:10.1080/14647273.2021.1955415] [PMID]
20. Kuroda K, Ikemoto Y, Horikawa T, Moriyama A, Ojiro Y, Takamizawa S, et al. Novel approaches to the management of recurrent pregnancy loss: The OPTIMUM (Optimization of thyroid function, thrombophilia, immunity, and uterine milieu) treatment strategy. Reprod Med Biol 2021; 20: 524-536. [DOI:10.1002/rmb2.12412] [PMID] [PMCID]
21. Nevers W, Pupco A, Koren G, Bozzo P. Safety of tacrolimus in pregnancy. Can Fam Physician 2014; 60: 905-906.
22. Barrueta OI, Martín EG, Sánchez PL, Herráiz ER, Bohórquez VM, Larisgoitia AA. [Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases]. Farm Hosp 2023; 47: T39-T49. (in Spanish) [DOI:10.1016/j.farma.2022.12.016] [PMID]
23. Nakagawa K, Kwak-Kim J, Hisano M, Kasahara Y, Kuroda K, Sugiyama R, et al. Obstetric and perinatal outcome of the women with repeated implantation failures or recurrent pregnancy losses who received pre- and post-conception tacrolimus treatment. Am J Reprod Immunol 2019; 82: e13142. [DOI:10.1111/aji.13142] [PMID]
24. Nakagawa K, Sugiyama R. Tacrolimus treatment in women with repeated implantation failures. Reprod Med Biol 2024; 23: e12558. [DOI:10.1002/rmb2.12558] [PMID] [PMCID]
25. Abdolmohammadi-Vahid S, Danaii S, Hamdi K, Jadidi-Niaragh F, Ahmadi M, Yousefi M. Novel immunotherapeutic approaches for treatment of infertility. Biomed Pharmacother 2016; 84: 1449-1459. [DOI:10.1016/j.biopha.2016.10.062] [PMID]
26. Nakagawa K, Kwak‐Kim J, Kuroda K, Sugiyama R, Yamaguchi K. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. Am J Reprod Immunol 2017; 78: e12682. [DOI:10.1111/aji.12682] [PMID]
27. Nakagawa K, Kwak‐Kim J, Ota K, Kuroda K, Hisano M, Sugiyama R, et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. Am J Reprod Immunol 2015; 73: 353-361. [DOI:10.1111/aji.12338] [PMID]
28. Albaghdadi AJH, Feeley CA, Kan FWK. Low-dose tacrolimus prevents dysregulated peri-conceptional ovarian and systemic immune cellular homeostasis in subjects with PCOS. Sci Rep 2019; 9: 6528. [DOI:10.1038/s41598-019-42960-x] [PMID] [PMCID]
29. Albaghdadi AJH, Kan FWK. Therapeutic potentials of low-dose tacrolimus for aberrant endometrial features in polycystic ovary syndrome. Int J Mol Sci 2021; 22: 2872. [DOI:10.3390/ijms22062872] [PMID] [PMCID]
30. Bahrami-Asl Z, Farzadi L, Fattahi A, Yousefi M, Quinonero A, Hakimi P, et al. Tacrolimus improves the implantation rate in patients with elevated Th1/2 helper cell ratio and repeated implantation failure (RIF). Geburtshilfe Frauenheilkd 2020; 80: 851-862. [DOI:10.1055/a-1056-3148] [PMID] [PMCID]
31. Albaghdadi AJH, Coyle K. Low-dose tacrolimus promotes the migration and invasion and nitric oxide production in the human-derived first trimester extravillous trophoblast cells in vitro. Int J Mol Sci 2022; 23: 8426. [DOI:10.3390/ijms23158426] [PMID] [PMCID]
32. Liu J, Li M, Fu J, Yuan G, Li N, Fu Y, et al. Tacrolimus improved the pregnancy outcomes of patients with refractory recurrent spontaneous abortion and immune bias disorders: A randomized controlled trial. Eur J Clin Pharmacol 2023; 79: 627-634. [DOI:10.1007/s00228-023-03473-9] [PMID]
33. Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N, et al. A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: Study from two Japanese tertiary referral centers. Arthritis Res Ther 2024; 26: 15. [DOI:10.1186/s13075-023-03256-8] [PMID] [PMCID]
34. Le HL, Francke MI, Andrews LM, de Winter BCM, van Gelder T, Hesselink DA. Usage of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and its implications for therapeutic drug monitoring: A systematic critical review. Ther Drug Monit 2020; 42: 518-531. [DOI:10.1097/FTD.0000000000000769] [PMID]
35. Saad AF, Pacheco LD, Saade GR. Immunosuppressant medications in pregnancy. Obstet Gynecol 2024; 143: e94-e106. [DOI:10.1097/AOG.0000000000005512] [PMID]
36. Akiyama S, Hamdeh S, Murakami N, Cotter TG, Suzuki H, Tsuchiya K. Pregnancy and neonatal outcomes in women receiving calcineurin inhibitors: A systematic review and meta-analysis. Br J Clin Pharmacol 2022; 88: 3950-3961. [DOI:10.1111/bcp.15414] [PMID]
37. Azizi G, Tavakol M, Yazdani R, Delavari S, Moeini Shad T, Rasouli SE, et al. Autoimmune manifestations among 461 patients with monogenic inborn errors of immunity. Pediatr Allergy Immunol 2021; 32: 1335-1348. [DOI:10.1111/pai.13510] [PMID]
38. Shen P, Zhang T, Han R, Xie H, Lv Q. Co-administration of tacrolimus and low molecular weight heparin in patients with a history of implantation failure and elevated peripheral blood natural killer cell proportion. J Obstet Gynaecol Res 2023; 49: 649-657. [DOI:10.1111/jog.15500] [PMID]
39. Hisano M, Nakagawa K, Suzuki T, Sugiyama R, Yamaguchi K. Immunosuppressive therapy with tacrolimus is a potential drug candidate for the prevention of unexplained or preeclamptic stillbirths with Th1-dominant immune states: A case series of five patients. J Matern Fetal Neonatal Med 2023; 36: 2258254. [DOI:10.1080/14767058.2023.2258254] [PMID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
